Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures

PLoS Medicine

Volumn 9, Issue 8, 2012, Pages

  Kesselheim, Aaron S ^a   Wang, Bo ^a   Studdert, David M ^b   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CITATION ANALYSIS; CONFLICT OF INTEREST; DRUG MANUFACTURE; DRUG MARKETING; HUMAN; INFORMATION RETRIEVAL; INTERPERSONAL COMMUNICATION; JOURNAL IMPACT FACTOR; LAW SUIT; MEDICAL LITERATURE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHYSICIAN; PUBLICATION; SCIENTIFIC LITERATURE; SCIENTIST; SENSITIVITY ANALYSIS; WHISTLEBLOWING;

AUTHORSHIP; CONFLICT OF INTEREST; DISCLOSURE; HUMANS; OFF-LABEL USE; PERIODICALS AS TOPIC; RESEARCH DESIGN;

EID: 84865543747     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001280     Document Type: Article

References (41)

1. Lexchin J, Bero LA, Djulbegovic B, Clark O, (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170.
2. Bekelman JE, Li Y, Gross CP, (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465.
3. Ridker PM, Torres J, (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 295: 2270-2274.
4. Sage WM, (2007) Some principles require principals: why banning "conflicts of interest" won't solve incentive problems in biomedical research. Texas Law Rev 85: 1413-1463.
5. Institute of Medicine, Board on Health Sciences Policy (2009) Conflict of interest in medical research, education, and practice. Washington, D.C.: NAS Press.
6. Harris G (26 Mar 2008) Cigarette company paid for lung cancer study. NY Times.
7. Meier B, Wilson D (17 Jul 2009) Medical school says former Army surgeon hid ties to Medtronic. NY Times. Available: http://www.nytimes.com/2009/07/15/business/15device.html. Accessed 10 July 2012.
8. Chimonas S, Frosch Z, Rothman DJ, (2011) From disclosure to transparency: the use of company payment data. Arch Intern Med 171: 81-86.
9. Okike K, Kocher MS, Wei EX, Mehlman CT, Bhandari M, (2009) Accuracy of conflict-of-interest disclosures reported by physicians. NEJM 361: 1466-1474.
10. Radley DC, Finkelstein SN, Stafford RS, (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166: 1021-1026.
11. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS, (2008) Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 28: 1443-1452.
12. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA, (2007) Characteristics and impact of drug detailing for gabapentin. PLoS Med 4 (4): e134 doi:10.1371/journal.pmed.0040134.
13. Chen H, Deshpande AD, Jiang R, Martin BC, (2005) An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 14: 629-638.
14. Kesselheim AS, Studdert DM, (2008) Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996-2005. Ann Intern Med 149: 342-349.
15. Weber T, Ornstein C (16 Sept 2011) Doctors avoid penalties in suits against medical firms. Available: http://www.propublica.org/article/doctors-avoid-penalties-in-suits-against-medical-firms. Accessed 28 May 2012.
16. Kesselheim AS, Mello MM, Studdert DM, (2011) Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 8 (4): e1000431 doi:10.1371/journal.pmed.1000431.
17. United States Department of Justice. Office of Public Affairs Press Releases. Available: www.usdoj.gov/03press/03_1_1.html. Accessed 28 May 2012.
18. LexisNexis. Total research system. Available: http://www.lexisnexis.com/en-us/home.page. Accessed 28 May 2012.
19. United States Judiciary. Public Access to Court Electronic Records. Available: http://pacer.psc.uscourts.gov/. Accessed 28 May 2012.
20. National Center for Biotechnology Information. PubMed. Available: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed 28 May 2012.
21. International Committee of Medical Journal Editors. ICMJE Form for Disclosure of Potential Conflicts of Interest. Available: http://www.icmje.org/coi_disclosure.pdf. Accessed 28 May 2012.
22. Kratochvil CJ, Vitiello B, Brent D, Bostic JQ, Naylor MW, (2006) Selecting an antidepressant for the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45: 371-373.
23. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, et al. (2007) Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 7: 1572-1583.
24. Fung JJ, (2004) Tacrolimus and transplantation: a decade in review. Transplantation 77: S41-S43.
25. Kelly DM, Demetris AJ, Fung JJ, Marcos A, Zhu Y, Subbotin V, et al. (2004) Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transplant 10: 253-263.
26. Bostic JQ, Schlozman S, Pataki C, Ristuccia C, Beresin EV, Martin A, (2003) From Alice Cooper to Marilyn Manson: the significance of adolescent antiheroes. Acad Psychiatry 27: 54-62.
27. Altman DG (1991) Practical Statistics for Medical Research. London, UK: Chapman and Hall.
28. Thomson Reuters. ISI Web of Knowledge Web site. Available: http://www.isiwebofknowledge.com. Accessed 28 May 2012.
29. R Development Core Team (2011) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
30. Harris G, Carey B, Roberts J (10 May 2007) Psychiatrists, children, and the drug industry's role. NY Times. Available: http://www.nytimes.com/2007/05/10/health/10psyche.html?pagewanted=all. Accessed 10 Jul 2012.
31. Weinfurt KP, Seils DM, Tzeng JP, Lin L, Schulman KA, Califf RM, (2008) Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. PLoS ONE 3 (5): e2128 doi:10.1371/journal.pone.0002128.
32. Drazen JM, de Leeuw PW, Laine C, et al. (2010) Toward more uniform conflict disclosures - the updated ICMJE conflict of interest reporting form. NEJM 363: 188-189.
33. Blum JA, Freeman K, Dart RC, Cooper RJ, (2009) Requirements and definitions in conflict of interest policies of medical journals. JAMA 302: 2230-2234.
34. Kesselheim AS, Lee JL, Avorn J, Servi A, Shrank WH, Choudhry NK, (2012) Conflict of interest in oncology publications: A survey of disclosure policies and statements. Cancer 118: 188-195.
35. Riechelmann R, Wang L, O'Carroll A, Krzyzanowska M, (2007) Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 25: 4642-4647.
36. Stern S, Lemmens T, (2010) Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles. PLoS Med 8 (8): e1001070 doi:10.1371/journal.pmed.1001070.
37. Chimonas S, Patterson L, Raveis VH, Rothman DJ, (2011) Managing conflicts of interest in clinical care: a national survey of policies at U.S. medical schools. Acad Med 86: 293-209.
38. Rockey SJ, Collins FS, (2010) Managing financial conflict of interest in biomedical research. JAMA 303: 2400-2402.
39. Wadman M, (1 August 2011) Conflict disclosure plan dropped. Nature 476: 17 doi:10.1038/476017a.
40. Tatsioni A, Siontis GC, Ioannidis JP, (2010) Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med 25: 914-919.
41. Wang AT, McCoy CP, Murad MH, Montori VM, (2010) Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 340: c1344 doi:10.1136/bmj.c1344.